Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 2/20 | 0.44 |
| ▸ | QPCT | Q16769 | 2/20 | 0.42 |
| ▸ | SLC2A4 | P14672 | 2/20 | 0.40 |
| ▸ | SLC2A8 | Q9NY64 | 1/20 | 0.40 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 6/20 | 0.40 |
| ▸ | CETP | P11597 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25425398 | 0.95 | PTGER2 (0.42) | PTGER2QPCTSLC2A4SLC2A8DGAT2 | |
| SCHEMBL30245811 | 0.95 | PTGER2 (0.42) | PTGER2QPCTSLC2A4SLC2A8DGAT2 | |
| SCHEMBL25428066 | 0.94 | PTGER2 (0.40) | PTGER2QPCTSLC2A4SLC2A8DGAT2 | |
| SCHEMBL25424668 | 0.94 | PTGER2 (0.40) | PTGER2QPCTSLC2A4SLC2A8DGAT2 | |
| SCHEMBL25424800 | 0.93 | PTGER2 (0.44) | PTGER2QPCTSLC2A4SLC2A8DGAT2 | |
| SCHEMBL30245444 | 0.92 | PTGER2 (0.40) | PTGER2QPCTSLC2A4SLC2A8DGAT2 | |
| SCHEMBL25424546 | 0.92 | PTGER2 (0.40) | PTGER2QPCTSLC2A4SLC2A8DGAT2 | |
| SCHEMBL25426210 | 0.91 | PTGER2 (0.38) | PTGER2QPCTSLC2A4SLC2A8DGAT2 | |
| SCHEMBL25425749 | 0.90 | PTGER2 (0.42) | PTGER2QPCTSLC2A4SLC2A8DGAT2 | |
| SCHEMBL25425923 | 0.88 | PTGER2 (0.43) | PTGER2QPCTSLC2A4SLC2A8DGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4384516-A1 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | Texas Heart Institute (US) | 2024-06-19 | — | — | EP | claimed |
| WO-2023018472-A9 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | TEXAS HEART INSTITUTE (US) | 2023-07-13 | — | — | WO | claimed |
| WO-2023018472-A1 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | TEXAS HEART INSTITUTE (US) | 2023-02-16 | — | — | WO | claimed |
| EP-4384516-A1 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | Texas Heart Institute (US) | 2024-06-19 | — | — | EP | disclosed |
| WO-2023018472-A9 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | TEXAS HEART INSTITUTE (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023018472-A1 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | TEXAS HEART INSTITUTE (US) | 2023-02-16 | — | — | WO | disclosed |